Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.09
BICX's Cash-to-Debt is ranked lower than
99.99% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 0.26 vs. BICX: 0.09 )
Ranked among companies with meaningful Cash-to-Debt only.
BICX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.13 Max: No Debt
Current: 0.09
Equity-to-Asset -11.03
BICX's Equity-to-Asset is ranked lower than
99.99% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. BICX: -11.03 )
Ranked among companies with meaningful Equity-to-Asset only.
BICX' s Equity-to-Asset Range Over the Past 10 Years
Min: -14.42  Med: 0.1 Max: 0.99
Current: -11.03
-14.42
0.99
Piotroski F-Score: 3
Altman Z-Score: -57.94
Beneish M-Score: -12.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -297.42
BICX's Operating Margin % is ranked lower than
99.99% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 6.49 vs. BICX: -297.42 )
Ranked among companies with meaningful Operating Margin % only.
BICX' s Operating Margin % Range Over the Past 10 Years
Min: -553.3  Med: -183.83 Max: -44.56
Current: -297.42
-553.3
-44.56
Net Margin % -638.39
BICX's Net Margin % is ranked lower than
99.99% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 4.00 vs. BICX: -638.39 )
Ranked among companies with meaningful Net Margin % only.
BICX' s Net Margin % Range Over the Past 10 Years
Min: -638.39  Med: -187.38 Max: -52.98
Current: -638.39
-638.39
-52.98
ROA % -392.30
BICX's ROA % is ranked lower than
99.99% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 3.51 vs. BICX: -392.30 )
Ranked among companies with meaningful ROA % only.
BICX' s ROA % Range Over the Past 10 Years
Min: -1550  Med: -123.71 Max: -18.07
Current: -392.3
-1550
-18.07
ROC (Joel Greenblatt) % -19115.38
BICX's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 210 Companies
in the Global Medical Care industry.

( Industry Median: 15.74 vs. BICX: -19115.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BICX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -102360  Med: -23057.15 Max: -6254.55
Current: -19115.38
-102360
-6254.55
3-Year Revenue Growth Rate -9.10
BICX's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 178 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. BICX: -9.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BICX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -18.9 Max: 14.5
Current: -9.1
0
14.5
3-Year EBITDA Growth Rate 74.70
BICX's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 158 Companies
in the Global Medical Care industry.

( Industry Median: 7.80 vs. BICX: 74.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BICX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 44.2 Max: 74.7
Current: 74.7
0
74.7
3-Year EPS without NRI Growth Rate 44.20
BICX's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 132 Companies
in the Global Medical Care industry.

( Industry Median: 8.30 vs. BICX: 44.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BICX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: 44.2
0
44.2
GuruFocus has detected 5 Warning Signs with BioCorRx Inc $BICX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BICX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BICX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621498    SIC: 8093
Compare:OTCPK:JRSS, AMEX:SSY, OTCPK:CVHIF, AMEX:AMS, OTCPK:WNDM, AMEX:HH, OTCPK:PFHO, OTCPK:QNIIF, OTCPK:BNKL, OTCPK:SPIN, OTCPK:LMNK, OTCPK:CPAI, OTCPK:FDNH, OTCPK:GRST, OTCPK:USNU, OTCPK:CAMDF, OTCPK:ATMS, OTCPK:GNOW, OTCPK:CCEL, NYSE:ADPT » details
BioCorRx Inc is an alcohol treatment and rehabilitation company. It provides an alcoholism treatment program that empowers patients to succeed in their overall recovery.

Fresh Start Private Management, Inc., a Nevada corporation on January 28, 2008 as Cetrone Energy Company. On July 26, 2010, the Company changed its name to Fresh Start Private Management Inc. Through its wholly owned subsidiary, it is an alcohol rehabilitation and treatment center. The company was established in January 2010 and is currently operating in Santa Ana, California. Its alcohol rehabilitation program consists of a Naltrexone implant that is placed under the skin in the lower abdomen coupled with life counseling sessions from specialized counselors. The Company operates within the Specialty Hospitals, Expert Psychiatric industry, specifically within the industry subsets of Alcoholism Rehabilitation Hospital. It has created an innovative alcohol treatment program that empowers patients to succeed in their overall recovery. The Company offers a treatment philosophy that combines medical intervention, a singular focus and a comprehensive approach, and a focus on family and friends. It has been operating for approximately 36 months and has treated over 150 patients. Currently, it is treating about 2 to 3 patients per week. The alcohol treatment services costs an average of $49,300 per patient and is typically covered by insurance. The Company faces competition with the other rehabilitation service providers.

Top Ranked Articles about BioCorRx Inc

America’s War on Drugs 'Forgotten people' are at greatest risk
President Donald Trump described them as America’s “forgotten people,” the less-educated white, middle-aged Americans. This group of individuals, together with the baby boomers and the so-called Generation X, are among the most vulnerable to heroin and prescription drug abuse. Several studies indicate that the number of drug overdose deaths among baby boomers, Generation X and less-educated white Americans has jumped in recent years. Read more...
Who Is Winning the Fight Against Opioid Abuse? A recent survey found approximately 23.5 million Americans are addicted to drugs and alcohol
The extent of the opioid epidemic in the U.S. is so pervasive that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Survey on Drug Use and Health estimated that around 23.5 million Americans, aged 12 or older, are addicted to drugs and alcohol. Read more...
Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...
BioCorRx Receives New Funding for Opioid Drug 21st Century Cures Act promises $1 billion in research funding
The signing last month of the 21st Century Cures Act into law by President Barack Obama signals a major revamp in the treatment of opioid addiction because of the promise of $1 billion in research funding, as well as a system to hasten approval of drugs and medicine devices by the Food and Drug Administration. Read more...

Ratios

vs
industry
vs
history
PS Ratio 30.00
BICX's PS Ratio is ranked lower than
99.99% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.49 vs. BICX: 30.00 )
Ranked among companies with meaningful PS Ratio only.
BICX' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6 Max: 185
Current: 30
0.95
185
Current Ratio 0.10
BICX's Current Ratio is ranked lower than
99.99% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. BICX: 0.10 )
Ranked among companies with meaningful Current Ratio only.
BICX' s Current Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.5 Max: 5.44
Current: 0.1
0.05
5.44
Quick Ratio 0.10
BICX's Quick Ratio is ranked lower than
99.99% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.16 vs. BICX: 0.10 )
Ranked among companies with meaningful Quick Ratio only.
BICX' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.5 Max: 5.44
Current: 0.1
0.05
5.44
Days Sales Outstanding 36.00
BICX's Days Sales Outstanding is ranked lower than
99.99% of the 174 Companies
in the Global Medical Care industry.

( Industry Median: 44.22 vs. BICX: 36.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
BICX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.05  Med: 160.29 Max: 452.04
Current: 36
11.05
452.04
Days Payable 2.00
BICX's Days Payable is ranked lower than
99.99% of the 140 Companies
in the Global Medical Care industry.

( Industry Median: 39.67 vs. BICX: 2.00 )
Ranked among companies with meaningful Days Payable only.
BICX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2
Current: 2
0
2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.70
BICX's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 126 Companies
in the Global Medical Care industry.

( Industry Median: -2.40 vs. BICX: -17.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BICX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19  Med: -7.3 Max: 39.3
Current: -17.7
-19
39.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 5.50
BICX's Price-to-Median-PS-Value is ranked lower than
99.99% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 1.05 vs. BICX: 5.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BICX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.9 Max: 13
Current: 5.5
0.2
13
Earnings Yield (Greenblatt) % -11.70
BICX's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.94 vs. BICX: -11.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BICX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.73  Med: 0 Max: 0
Current: -11.7
-11.73
0

More Statistics

Revenue (TTM) (Mil) $0.66
EPS (TTM) $ -0.03
Beta-0.37
Short Percentage of Float0.00%
52-Week Range $0.01 - 0.15
Shares Outstanding (Mil)169.89
» More Articles for BICX

Headlines

Articles On GuruFocus.com
Majority of US Employers: Prescription Drug Misuse Is Grounds for Termination Mar 21 2017 
America’s War on Drugs Mar 07 2017 
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
ANGEL Program Gets National Attention Feb 13 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
US Prisons Experiment With Addiction Treatment for Inmates Nov 29 2016 
Health Care Sector in an Upward Climb in June Jun 12 2014 
Two Promising Health Care Stocks with Market Capitalizations Under $500 Million Jun 11 2014 

More From Other Websites
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Mar 22 2017
BioCorRx Announces Upgrade to the OTCQB(R) Mar 22 2017
BioCorRx Announces Updates on Preclinical Studies of BICX101 and Pre-IND Meeting Request with FDA Mar 21 2017
Companies Aiming for the Billion-Dollar Opioid Addiction Market Mar 18 2017
BioCorRx to Present at the Sidoti & Company Spring 2017 Convention in NYC Mar 15 2017
BioCorRx Completes $940,000 Equity Financing and Announces Alpine Creek Capital has Agreed to Invest... Mar 10 2017
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Mar 09 2017
America's War on Drugs Mar 07 2017
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017
BioCorRx Provides Preclinical Study Update on BICX101 Development Feb 23 2017
Drug Addiction Treatment Stocks to Watch Feb 22 2017
BioCorRx Announces the Appointment of Dr. Balbir S. Brar as VP of Drug Development Feb 21 2017
ANGEL Program Gets National Attention Feb 13 2017
BioCorRx Provides Business Update Webcast Feb 10 2017
BioCorRx to Collaborate with the City of Anaheim to Treat Opioid and Alcohol Addiction Feb 08 2017
BIOCORRX INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Feb 08 2017
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017
JGR Capital Partners Initiates Coverage on BioCorRx Inc. with a Price Target of $0.09 Jan 19 2017
BioCorRx Retains Innovative Science Solutions to Guide FDA Regulatory Process for its Naltrexone... Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)